<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655352</url>
  </required_header>
  <id_info>
    <org_study_id>BCT-100-000</org_study_id>
    <nct_id>NCT04655352</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Bacillus Subtilis MB40 in Healthy Adult Volunteers</brief_title>
  <official_title>Single Center, Clinical Trial Examining the Safety and Tolerability of a Bacillus Subtilis Probiotic in Healthy Adult Volunteers in a Single-Blind Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BIO-CAT Microbials, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prism Research LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BIO-CAT Microbials, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-blind, placebo-lead in design examining the safety and tolerability of&#xD;
      a probiotic, Bacillus subtilis MB40. Subjects received a 7-day placebo BID lead-in and a&#xD;
      21-day BID course of Bacillus subtilis MB40. GI questionnaires and Bristol stool charts along&#xD;
      with evaluation of any medically significant changes, based on physical examination findings,&#xD;
      clinical laboratory tests and vital signs assessments were used to determine the safety and&#xD;
      tolerability of MB40.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2015</start_date>
  <completion_date type="Actual">December 17, 2015</completion_date>
  <primary_completion_date type="Actual">December 17, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>GI Questionnaire and weekly in person assessment of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weekly mean of daily frequency of GI symptoms</measure>
    <time_frame>4 weeks</time_frame>
    <description>GI symptom frequency and severity questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean of daily severity of GI symptoms</measure>
    <time_frame>4 weeks</time_frame>
    <description>GI symptom frequency and severity questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency of bowel movements</measure>
    <time_frame>4 weeks</time_frame>
    <description>Bristol Stool Chart questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal vital signs</measure>
    <time_frame>Screening and day 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal complete blood panel</measure>
    <time_frame>Screening and day 29</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Bacillus subtilis MB40</arm_group_label>
    <description>1-week placebo (maltodextrin and excipients) lead-in followed by MB40 intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bacillus subtilis MB40</intervention_name>
    <description>1-week placebo (maltodextrin and excipients) lead-in followed by 250 mg capsule (5 billion CFU/capsule) administered twice daily for 21 days</description>
    <arm_group_label>Bacillus subtilis MB40</arm_group_label>
    <other_name>OPTI-BIOME MB40</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Human volunteers meeting eligibility criteria listed above.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Normal, healthy adult volunteers aged 18 to 55 years.&#xD;
&#xD;
          2. BMI of 18 to 32 kg/m2 (inclusive)&#xD;
&#xD;
          3. Have no clinically significant findings on screening evaluations (clinical,&#xD;
             laboratory)&#xD;
&#xD;
          4. If female, participant is not of child bearing potential, which is defined as females&#xD;
             who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are&#xD;
             post-menopausal (natural or surgically with &gt; 1 year since last menstruation) OR&#xD;
&#xD;
             Females of childbearing potential must agree to use a medically approved method of&#xD;
             birth control and have a negative urine pregnancy test result. Acceptable methods of&#xD;
             birth control include:&#xD;
&#xD;
               -  Hormonal contraceptives (stable for 1 month) including oral contraceptives,&#xD;
                  hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing),&#xD;
                  injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant&#xD;
                  System)&#xD;
&#xD;
               -  Double-barrier method&#xD;
&#xD;
               -  Intrauterine devices&#xD;
&#xD;
               -  Non-heterosexual lifestyle or agrees to use contraception if planning on changing&#xD;
                  to heterosexual partner(s)&#xD;
&#xD;
               -  Vasectomy of partner (shown successful as per appropriate follow-up)&#xD;
&#xD;
          5. Able to comprehend and willing to sign an Informed Consent Form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or clinical manifestations of significant metabolic, hepatic, renal,&#xD;
             hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological,&#xD;
             or psychiatric disorders.&#xD;
&#xD;
          2. Current or recent history (&lt;30 days prior to Screening) of a clinically significant&#xD;
             bacterial, fungal, or mycobacterial infection.&#xD;
&#xD;
          3. Frequent GERD, indigestion, nausea, or vomiting (1 or more days per week).&#xD;
&#xD;
          4. Frequent abdominal pain/cramps or bloating (1 or more days per week).&#xD;
&#xD;
          5. Frequent constipation, diarrhea, or alternating constipation/diarrhea (1 or more days&#xD;
             per week).&#xD;
&#xD;
          6. Abdominal pain before bowel movements that is relieved with defecation (most bowel&#xD;
             movements).&#xD;
&#xD;
          7. Abdominal complaints often worsened by worry or tension (1 or more days per week).&#xD;
&#xD;
          8. Medical diagnosis of esophagitis, gastritis, ulcers, inflammatory bowel disease,&#xD;
             gastrointestinal cancer, celiac disease, or irritable bowel syndrome.&#xD;
&#xD;
          9. Recent gastrointestinal bleeding (hematemesis, hematochezia, melena in past 3 months)&#xD;
             or anemia in the past 3 months.&#xD;
&#xD;
         10. Unintentional weight loss of 10 lbs or more in the past 3 months.&#xD;
&#xD;
         11. Screening GI Questionnaire Score of ≥ 4 for any single item.&#xD;
&#xD;
         12. Current clinically significant viral infection&#xD;
&#xD;
         13. History of malignancy, with the exception of cured basal cell or squamous cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
         14. Resting heart rate less than 45 bpm or greater than 100 bpm.&#xD;
&#xD;
         15. History of unstable ischemic heart disease or uncontrolled hypertension (blood&#xD;
             pressure &gt;150/90 mm Hg)&#xD;
&#xD;
         16. History of stomach or intestinal surgery, except that appendectomy and/or&#xD;
             cholecystectomy will be allowed.&#xD;
&#xD;
         17. Presence of a malabsorption syndrome possibly affecting drug/Product absorption (e.g.,&#xD;
             Crohn's disease or chronic pancreatitis)&#xD;
&#xD;
         18. History of alcoholism or drug addiction within 1 year prior to Screening, or current&#xD;
             alcohol or drug use that, in the opinion of the investigator, will interfere with the&#xD;
             subject's ability to comply with the dosing schedule and study evaluations.&#xD;
&#xD;
         19. Use of any tobacco-containing or nicotine-containing products (including cigarette,&#xD;
             pipe, cigar, chewing tobacco, nicotine patch, or nicotine gum) more frequently than 50&#xD;
             cigarettes per week within 2 months prior to Screening or &gt; 20 per week from screen&#xD;
             through the end of the study&#xD;
&#xD;
         20. Current treatment or treatment within 30 days or 5 half-lives (t ½) prior to the first&#xD;
             dose of study product with another investigational product or current enrollment in&#xD;
             another investigational drug protocol at the time of screening.&#xD;
&#xD;
         21. Use of any over-the-counter, prescription, non-prescription preparations (including&#xD;
             vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations), within 7&#xD;
             days prior to study entry, unless deemed acceptable by the Investigator.&#xD;
&#xD;
         22. Use of greater that 2 units per day of alcohol-containing or caffeine-containing foods&#xD;
             or beverages within 72 hours prior to study entry and throughout the duration of the&#xD;
             study.&#xD;
&#xD;
         23. Donation of blood in excess of 500 ml within 4 weeks prior to study entry or of plasma&#xD;
             within 2 weeks prior to Screening.&#xD;
&#xD;
         24. Receipt of blood products within 3 months prior to study entry.&#xD;
&#xD;
         25. Subjects who, in the opinion of the investigator, are unable or unlikely to comply&#xD;
             with the dosing schedule and study evaluations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Matson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Prism Research LLC</affiliation>
  </overall_official>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

